FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to clinical laboratory diagnostics, and is intended for determining minimum residual disease (MRD) by multiparameter flow cytometry (MFC) in patients with B-linear acute lymphoblastic leukaemia (B-ALL) receiving CD19-directed immunotherapy. To detect residual tumour cells in the bone marrow aspirate, a panel of antibodies is used, which includes antibodies to CD10, CD34, CD58, CD38, CD20, CD45, CD19. Also relates to additional B-linear antigens CD22, CD24 and CD79a. Number of residual tumour cells in the bone marrow is assessed.
EFFECT: invention provides an original method for determining MRD by MFC in patients with B-ALL receiving CD19-directed immunotherapy, which enables to monitor the results of therapy with high efficiency, which is not inferior to molecular diagnostic methods.
1 cl, 6 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TUMOUR B LYMPHOBLASTS AVAILABILITY MARKERS DETERMINATION | 2015 |
|
RU2638800C2 |
| METHOD OF ASSESSING MINIMAL RESIDUAL DISEASE (MRD) BY MULTICOLOR FLOW CYTOMETRY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN THE POST-INDUCTION PHASE OF TREATMENT | 2022 |
|
RU2802131C1 |
| METHOD FOR DETERMINING MARKERS OF PRESENCE OF TUMOR T-LYMPHOBLASTS | 2016 |
|
RU2674994C2 |
| METHOD FOR PREDICTION OF RESPONSE TO ANTICANCER THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA | 2023 |
|
RU2814269C1 |
| METHODS FOR DIAGNOSING AND INDUCING LEUKAEMIA/LYMPHOMA | 2010 |
|
RU2574987C2 |
| METHOD FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA FROM PROGENITOR B-CELLS WITH REARRANGEMENTS IN THE KMT2A GENE IN CHILDREN OF THE FIRST YEAR OF LIFE | 2022 |
|
RU2797687C1 |
| SET OF OLIGODEOXYRIBONUCLEOTIDE PRIMERS AND FLUORESCENTLY LABELED DNA PROBES FOR DETERMINING THE EXPRESSION OF THE SOCS2, CD34, FAM30A, GPR56, DNMT3B, SPINK2 GENES, FOLLOWED BY DETERMINING THE LEVEL OF RELATIVE EXPRESSION RELATIVE TO THE ABL1 REFERENCE GENE, AMPLIFIED IN REAL-TIME PCR, USED TO PREDICT THE RISK OF EARLY RELAPSE IN CHILDREN WITH ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | 2022 |
|
RU2783950C1 |
| METHOD OF THE DIFFERENTIAL DIAGNOSIS OF ACUTE LEUKEMIA USING A CELLULAR BIOCHIP | 2017 |
|
RU2681651C1 |
| METHOD FOR PREDICTING THE COURSE OF CHRONIC LYMPHOCYTIC LEUKEMIA | 2022 |
|
RU2788816C1 |
| T CELLS RE-TARGETED WITH RESPECT TO CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR, AND METHODS FOR USE THEREOF | 2014 |
|
RU2711114C2 |
